Search results
Results from the WOW.Com Content Network
Pravastatin, sold under the brand name Pravachol among others, is a statin medication, used for preventing cardiovascular disease in those at high risk and treating abnormal lipids. [5] It is suggested to be used together with diet changes, exercise, and weight loss. [ 5 ]
Pravastatin belongs to the group called statins. [2] It reduces total blood cholesterol by blocking the action of 3-hydroxy-3-methyl-glutaryl-coenzyme-A (HMG-CoA) reductase, an enzyme in the liver involved in the production of cholesterol. [ 2 ]
[24] [25] In 2008, sales totalled $11.08 billion, $13.9 billion in 2009, and in 2010 total sales rose to $16.1 billion, of which a major portion was in Europe and North America. On December 23, 2008, Teva acquired Barr Pharmaceuticals for $7.5 billion, making Barr and Pliva (which Barr bought earlier) part of Teva.
A delayed release or late release may refer to: Delayed release (film), the delayed release of a film to the public; Delayed release (pharmacology), oral medicines that do not immediately disintegrate and release the active ingredient(s) into the body [+delayed release], a distinctive feature given to affricate consonants in phonology
Fenofibrate (sold under the brand name Tricor among others), is an oral medication of the fibrate class used to treat abnormal blood lipid levels. [3] It is less commonly used compared to statins because it treats a different type of cholesterol abnormality to statins.
Panadol Rapid Handipak is Panadol Rapid packaged in a slim container of ten 500 mg caplets, designed to appeal to Australian women who are 20 to 35 years of age. [ 24 ] [ 25 ] Panadol Cold and Catarrh contains three active ingredients: paracetamol, phenylephrine hydrochloride as a nasal decongestant, and chlorpheniramine maleate to prevent ...
A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx.
Rabeprazole-ER was a 50 mg capsule composed of five non-identical 10 mg tablets that were designed to release rabeprazole at differing intervals throughout the gastrointestinal system. However, because two high quality clinical trials failed to demonstrate a benefit of rabeprazole-ER versus esomeprazole (another common PPI) for healing grade C ...